Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Sickle Cell Disease Treatment Market, by Treatment
1.4.2 Europe Sickle Cell Disease Treatment Market, by End-Use
1.4.3 Europe Sickle Cell Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Europe Sickle Cell Disease Treatment Market by Treatment
5.1 Europe Blood Transfusion Market by Country
5.2 Europe Pharmacotherapy Market by Country
5.3 Europe Bone Marrow Transplant Market by Country
Chapter 6. Europe Sickle Cell Disease Treatment Market by End-use
6.1 Europe Hospitals Market by Country
6.2 Europe Specialty Clinics Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Sickle Cell Disease Treatment Market by Country
7.1 Germany Sickle Cell Disease Treatment Market
7.1.1 Germany Sickle Cell Disease Treatment Market by Treatment
7.1.2 Germany Sickle Cell Disease Treatment Market by End-use
7.2 UK Sickle Cell Disease Treatment Market
7.2.1 UK Sickle Cell Disease Treatment Market by Treatment
7.2.2 UK Sickle Cell Disease Treatment Market by End-use
7.3 France Sickle Cell Disease Treatment Market
7.3.1 France Sickle Cell Disease Treatment Market by Treatment
7.3.2 France Sickle Cell Disease Treatment Market by End-use
7.4 Russia Sickle Cell Disease Treatment Market
7.4.1 Russia Sickle Cell Disease Treatment Market by Treatment
7.4.2 Russia Sickle Cell Disease Treatment Market by End-use
7.5 Spain Sickle Cell Disease Treatment Market
7.5.1 Spain Sickle Cell Disease Treatment Market by Treatment
7.5.2 Spain Sickle Cell Disease Treatment Market by End-use
7.6 Italy Sickle Cell Disease Treatment Market
7.6.1 Italy Sickle Cell Disease Treatment Market by Treatment
7.6.2 Italy Sickle Cell Disease Treatment Market by End-use
7.7 Rest of Europe Sickle Cell Disease Treatment Market
7.7.1 Rest of Europe Sickle Cell Disease Treatment Market by Treatment
7.7.2 Rest of Europe Sickle Cell Disease Treatment Market by End-use
Chapter 8. Company Profiles
8.1 bluebird bio, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.3.4 Recent strategies and developments:
8.3.4.1 Trials and Approvals:
8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
8.4.1 Company Overview
8.4.2 Recent strategies and developments:
8.4.2.1 Trials and Approvals:
8.4.3 SWOT Analysis
8.5 CSL Limited
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental & Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Trials and Approvals:
8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Product Launches and Product Expansions:
8.10.4.3 Trials and Approvals:
8.10.5 SWOT Analysis
Unique Offerings 